Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease StudyDual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study
(MedPage Today) — PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) in high-risk patients with… (MedPage Today) — PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular Read More
Discovery of breast cancer treatment resistance mechanism could lead to new hope for someDiscovery of breast cancer treatment resistance mechanism could lead to new hope for some
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets cancer cells with a strong chemotherapy drug. For many patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancers, ADCs such as trastuzumab deruxtecan (T-DXd) have dramatically improved outcomes.
Obesity Drops in Adults; Wegovy’s Heart Protection; Women Turn to TestosteroneObesity Drops in Adults; Wegovy’s Heart Protection; Women Turn to Testosterone
(MedPage Today) — The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an all-time high, at 13.8%, according to a Gallup survey. Over a 10-year span, GLP-1 receptor agonists weren… (MedPage Today) — The obesity rate for adults in the Read More
Journalist Robin Davis Opens Up About Her Breast Cancer JourneyJournalist Robin Davis Opens Up About Her Breast Cancer Journey
Robin Davis, an Emmy-award winning journalist and a two-time breast cancer survivor, joins TODAY to talk about her new book called “Surviving Paris: A Memoir of Healing in the City of Light.” She opens up about what it was like being diagnosed while she was living in Paris, how she was able to find support from Hoda Kotb and more.
AI tool identifies women at high risk of interval breast cancerAI tool identifies women at high risk of interval breast cancer
In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancer, which is breast cancer that is diagnosed between regular screening mammograms. Results of the new study were published today in Radiology.
STAT+: Pharmalittle: We’re reading about rising GLP-1 use, a psychedelic therapy for depression, and moreSTAT+: Pharmalittle: We’re reading about rising GLP-1 use, a psychedelic therapy for depression, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have cool breezes and clear blue skies greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for Read More
Outdoor air pollution linked to higher incidence of breast cancerOutdoor air pollution linked to higher incidence of breast cancer
Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more than 400,000 women and 28,000 breast cancer cases.
Breastfeeding linked to lasting immune protection against breast cancerBreastfeeding linked to lasting immune protection against breast cancer
A team of researchers led by Peter Mac’s Professor Sherene Loi has uncovered how having children and breastfeeding reduces a woman’s long-term risk of breast cancer.
Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal WomenTirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women
(MedPage Today) — ORLANDO — Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual GIP/GLP-1 receptor agonist tirzepatide than their counterparts not using HT, according to a retrospective… (MedPage Today) — ORLANDO — Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual Read More
Weight-loss drugs like Ozempic may also curb drug and alcohol addictionWeight-loss drugs like Ozempic may also curb drug and alcohol addiction
GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, and nicotine use. Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy. GLP-1 drugs, originally developed Read More